Pre-Commercial Value Assessment of a Nuclear Medicine Pair to Diagnose and Treat Neuroendocrine Tumors (NET)

Publications
Category:
Published on:
August 1, 2020
Written by:
Piergiulio Lauriano

When our client, a leading radiopharmaceutical company, needed support to understand the commercial opportunity represented by a Phase III radiopharmaceutical and its diagnostic radiotracer companion, Alira Health stepped in to run a comprehensive analysis.

Read on to learn how our team analyzed the market, assessed value assets, and helped our client move forward with confidence.

For more information, please contact Piergiulio Lauriano.

For more information about Alira Health’s Management Consulting services

Click here

Related news

Due Diligence Pharma
News July 21, 2021
Alira Health Announces its Role as Strategic Advisor to Naxicap
Alira Health is proud to announce its role as strategic advisor to Naxicap in the equity investment in Ceres Pharma Bv.
MedTech Pharma
Events June 30, 2021
Event: Bio Asia-Taiwan
Join Daniela Sica, Vice President, Business Development, Pharma & Biotech, and Shu-Ling Cheng, Partner, at Biotechnology Innovation Organization's Bio-Asia Taiwan July 21-25, 2021.
Due Diligence MedTech Patient Engagement Pharma
Multimedia April 12, 2021
Evolution of the Drug Delivery Systems Industry and its Increasing Role in Driving Patient Outcomes
In the third episode, Amira Ghozali, Aptar Pharma, Kenny Carberry, and Aude Ouensanga, discuss the evolution of the DDS industry, its relationship with Pharma, and its increasing role(...)
M&A MedTech Pharma
News April 12, 2021
Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
MedTech Pharma
Publications February 8, 2021
Infographic: 2021 Trends in Healthcare
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
MedTech Pharma
News February 4, 2021
2020 Year in Review
With 2021 in full swing, we want to take a moment to reflect on last year’s achievements and congratulate the entire Alira Health Team for their hard work and dedication to healthcare(...)
M&A Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.